Aratana Therapeutics receives first FDA approval
Aratana Therapeutics has received Food And Drug Administration (FDA) approval of Galliprant (grapiprant tablets), according to a company release. The medication is used for the control of pain and inflammation associated with osteoarthritis in dogs and is expected to be available in fall 2016.
Galliprant is a prostaglandin E2 (PGE2) EP4 receptor antagonist (PRA), a non-cyclooxygenase inhibiting, nonsteroidal anti-inflammatory drug, which blocks PGE2-elicited pain and inflammation.
"As the first approved product in the new piprant class, Galliprant offers veterinarians a needed therapeutic option for the millions of dogs treated each year for osteoarthritis," says Steven St. Peter, MD, president and CEO of Aratana, in the release. "Clinical studies have shown Galliprant offers proven efficacy when compared to placebo and is well-tolerated in dogs."